{
    "clinical_study": {
        "@rank": "65383", 
        "arm_group": [
            {
                "arm_group_label": "CV9104", 
                "arm_group_type": "Active Comparator", 
                "description": "CV9104 intradermal injection"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo intradermal injection"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether the new RNActive-derived prostate cancer\n      vaccine CV9104 prolongs survival in patients with asymptomatic or minimally symptomatic\n      metastatic  prostate cancer that is castrate resistant."
        }, 
        "brief_title": "Trial of RNActive\u00ae-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The study is the first clinical study with the new prostate cancer vaccine CV9104. This\n      vaccine is composed of 6 RNActive-based compounds, each encoding for an antigen that is\n      overexpressed in prostate cancer compared to healthy tissues. RNActive-based vaccines are a\n      novel class of vaccines based on messenger RNA.\n\n      The study is a double-blind randomized placebo-controlled phase I/II trial in men with\n      asymptomatic- minimally symptomatic metastatic castrate-refractory prostate cancer.\n\n      The phase 1 (safety lead- in) part of the trial has the primary objective to assess the\n      safety of CV9104 and to determine the dose for the randomized phase II part.\n\n      The primary objective of the phase II part is to compare overall survival in patients\n      treated with CV9104 compared to patients treated with placebo."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          1. Male, age \u226518 years\n\n          2. Histologically confirmed castrate refractory metastatic adenocarcinoma of the\n             prostate with progressive disease after surgical castration or during androgen\n             suppression therapy including a GNRH agonist or antagonist and after at least 1\n             additional anti-hormonal manipulation; and serum testosterone level of < 50 ng/dL or\n             < 1.7 nmol/L\n\n             Progression will be confirmed either\n\n               -  radiologically or\n\n               -  by 2 consecutive rises of PSA, measured at least 1 week apart, resulting at\n                  least in a 50% increase over the nadir and a PSA > 2 ng/mL.\n\n               -  An antiandrogen withdrawal response must have been excluded after\n                  discontinuation of antiandrogen therapy for at least 6 weeks.\n\n          3. Metastatic disease confirmed by imaging\n\n          4. ECOG performance status 0 or 1\n\n        Key Exclusion Criteria:\n\n          1. Previous immunotherapy for PCA (e.g.  sipuleucel-T [Provenge\u00ae], experimental cancer\n             vaccines or ipilimumab [Yervoy\u00ae]).\n\n          2. Treatment with any investigational anticancer agents within 4 weeks prior to first\n             dose of study drug\n\n          3. Systemic treatment with immunosuppressive agents\n\n          4. Active skin disease (atopic eczema, psoriasis) in the areas for vaccine injection\n             (upper arms or thighs) preventing the administration of i.d. injections into areas of\n             healthy skin.\n\n          5. History of or current autoimmune disorders\n\n          6. Primary or secondary immune deficiency.\n\n          7. Seropositive for human immunodeficiency virus, hepatitis B virus (except after\n             hepatitis B vaccination) or hepatitis C virus infection.\n\n          8. Symptomatic congestive heart failure (New York Heart Association 3 or 4), unstable\n             angina pectoris or myocardial infarction, significant cardiac arrhythmia, history of\n             stroke or transient ischemic attack, all within 6 months prior to enrolment or severe\n             hypertension according to WHO criteria or uncontrolled hypertension at the time of\n             enrolment (systolic blood pressure \u2265 180 mm Hg)\u00b4\n\n          9. Previous chemotherapy for metastatic PCA.\n\n         10. Previous anti-hormonal treatment with abiraterone or any other investigational\n             anti-hormonal treatment.\n\n         11. Cancer-related pain requiring opioid narcotics within 28 days before enrolment or an\n             average pain score of > 3 on a visual analogue scale.\n\n         12. Presence of visceral metastases.\n\n         13. History of other malignancies other than PCA over the last 5 years (except basal cell\n             carcinoma of the skin)."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "197", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01817738", 
            "org_study_id": "CV-9104-004"
        }, 
        "intervention": [
            {
                "arm_group_label": "CV9104", 
                "description": "Intradermal injection of CV9104", 
                "intervention_name": "CV9104", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Intradermal injection of placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metastatic", 
            "Castrate-refractory"
        ], 
        "lastchanged_date": "December 19, 2013", 
        "link": {
            "description": "Click here for more information about CureVac", 
            "url": "http://www.curevac.de"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chomutov", 
                        "country": "Czech Republic", 
                        "zip": "430 12"
                    }, 
                    "name": "Krajsk\u00e1 zdravotn\u00ed, a.s. - Nemocnice Chomutov, o.z.Onkologick\u00e9 odd\u011blen\u00ed"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Olomouc", 
                        "country": "Czech Republic", 
                        "zip": "779 00"
                    }, 
                    "name": "Fakultn\u00ed nemocnice Olomouc, Urologick\u00e1 klinika"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pardubice", 
                        "country": "Czech Republic", 
                        "zip": "532 03"
                    }, 
                    "name": "Multiscan, a.s, Odd\u011blen\u00ed klinick\u00e9 a radia\u010dn\u00ed onkologie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha", 
                        "country": "Czech Republic", 
                        "zip": "140 59"
                    }, 
                    "name": "Thomayerova nemocnice, Urologick\u00e9 odd\u011blen\u00ed"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Usti nad Labem", 
                        "country": "Czech Republic", 
                        "zip": "401 13"
                    }, 
                    "name": "Krajsk\u00e1 zdravotn\u00ed, a.s. - Masarykova nemocnice \u00dast\u00ed nad Labem"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif cedex", 
                        "country": "France"
                    }, 
                    "name": "Institut Gustave Roussy"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aachen", 
                        "country": "Germany", 
                        "zip": "D-52074"
                    }, 
                    "name": "Universit\u00e4tsklinikum Aachen Klinik f\u00fcr Urologie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "D-10967"
                    }, 
                    "name": "Vivantes Klinikum Am Urban Klinik f\u00fcr Urologie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bonn", 
                        "country": "Germany", 
                        "zip": "53111"
                    }, 
                    "name": "Medizinisches Zentrum"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "zip": "D-01307"
                    }, 
                    "name": "Universit\u00e4tsklinikum Dresden Klinik und Poliklinik f\u00fcr Urologie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Freiburg", 
                        "country": "Germany", 
                        "zip": "D-79106"
                    }, 
                    "name": "Chirurgische Universit\u00e4tsklinik Freiburg Klinik f\u00fcr Urologie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamburg", 
                        "country": "Germany", 
                        "zip": "22081"
                    }, 
                    "name": "Urologikum Hamburg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "zip": "D-69120"
                    }, 
                    "name": "Nationales Zentrum f\u00fcr Tumorerkrankungen Medizinische Onkologie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany"
                    }, 
                    "name": "Urologie am Nordplatz"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mannheim", 
                        "country": "Germany"
                    }, 
                    "name": "UMM Universit\u00e4tsmedizin Mannheim"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marklleeberg", 
                        "country": "Germany", 
                        "zip": "04416"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Munich", 
                        "country": "Germany", 
                        "zip": "D-81675"
                    }, 
                    "name": "Urologische Klinik und Poliklinik der Technischen Universit\u00e4t M\u00fcnchen Klinikum Rechts der Isar"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00fcnster", 
                        "country": "Germany", 
                        "zip": "D-48149"
                    }, 
                    "name": "Universit\u00e4tsklinikum M\u00fcnster Klinik und Poliklinik f\u00fcr Urologie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "N\u00fcrtingen", 
                        "country": "Germany", 
                        "zip": "D-72622"
                    }, 
                    "name": "Studienpraxis f\u00fcr Urologie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Offenburg", 
                        "country": "Germany"
                    }, 
                    "name": "Ortenau Klinikum"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Planegg", 
                        "country": "Germany", 
                        "zip": "82152"
                    }, 
                    "name": "Urologische Klinik"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "T\u00fcbingen", 
                        "country": "Germany", 
                        "zip": "D-72076"
                    }, 
                    "name": "Universit\u00e4tsklinik f\u00fcr Urologie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krakow", 
                        "country": "Poland"
                    }, 
                    "name": "Medica Pro Familia Krakow"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mys\u0142owice", 
                        "country": "Poland"
                    }, 
                    "name": "Centrum Urologiczne Sp. z o.o."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warsaw", 
                        "country": "Poland"
                    }, 
                    "name": "NZOZ Magodent, Centrum Medyczne Ostrobramska, Oncologii Klinicznej i Chem\u00edoterapii"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warsaw", 
                        "country": "Poland"
                    }, 
                    "name": "Centralny Szpital Kliniczny MSWiA, Klinika Onkologii I Hematologii"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warsaw", 
                        "country": "Poland"
                    }, 
                    "name": "Szpital Sw. El\u017cbiety"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warsaw", 
                        "country": "Poland"
                    }, 
                    "name": "Instytut M. Curie-Sk\u0142odowskiej"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wroclaw", 
                        "country": "Poland"
                    }, 
                    "name": "Szpital Uniwersytecki, Katedra i Klinika Urologii i Onkologii Urologicznej"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wroclaw", 
                        "country": "Poland"
                    }, 
                    "name": "Profesorskie Centrum Medyczne OPTIMUM Wroc\u0142aw"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28050"
                    }, 
                    "name": "Hospital de Madrid Norte Sanchinarro Centro Integral Oncol\u00f3gico Clara Campal (CIOCC)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Malaga", 
                        "country": "Spain"
                    }, 
                    "name": "Hospital Cl\u00ednico Virgen de la Victoria Campus Universitario de Teatinos s/n"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pamplona", 
                        "country": "Spain", 
                        "zip": "31008"
                    }, 
                    "name": "Cl\u00ednica Universitaria de Navarra Departamento de Oncolog\u00eda"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santiago de Compostela", 
                        "country": "Spain", 
                        "zip": "15703"
                    }, 
                    "name": "Complejo Hospitalario Universitario Santiago Departamento de Oncolog\u00eda"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Valencia", 
                        "country": "Spain", 
                        "zip": "46009"
                    }, 
                    "name": "Instituto Valenciano de Oncolog\u00eda"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gothenburg", 
                        "country": "Sweden", 
                        "zip": "413 45"
                    }, 
                    "name": "\"Sahlgrenska Universitetssjukhuset Urologmottagningen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Malm\u00f6", 
                        "country": "Sweden", 
                        "zip": "20502"
                    }, 
                    "name": "Sk\u00e5nes Universitetssjukhus Malm\u00f6 Urologmottagningen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden", 
                        "zip": "171 76"
                    }, 
                    "name": "Karolinska Universitetssjukhuset Solna Urologiska kliniken"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Uppsala", 
                        "country": "Sweden", 
                        "zip": "751 85"
                    }, 
                    "name": "Akademiska sjukhuset Urologmottagningen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "\u00d6rebro", 
                        "country": "Sweden", 
                        "zip": "701 85"
                    }, 
                    "name": "Universitetssjukhuset \u00d6rebro Urologmottagningen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Basel", 
                        "country": "Switzerland", 
                        "zip": "4031"
                    }, 
                    "name": "Universit\u00e4tsspital Basel Medizinische Onkologie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chur", 
                        "country": "Switzerland", 
                        "zip": "7000"
                    }, 
                    "name": "Kantonsspital Chur Department Innere Medizin H\u00e4matologie und Onkologie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lausanne", 
                        "country": "Switzerland", 
                        "zip": "1011"
                    }, 
                    "name": "CHUV"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Gallen", 
                        "country": "Switzerland", 
                        "zip": "9007"
                    }, 
                    "name": "Kantonsspital St. Gallen Department Innere Medizin H\u00e4matologie Medizinische Onkologie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Borough of Wirral", 
                        "country": "United Kingdom", 
                        "zip": "CH64 4JY"
                    }, 
                    "name": "Clatterbridge Cancer Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Royal Free Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nottingham", 
                        "country": "United Kingdom", 
                        "zip": "NG5 1PB"
                    }, 
                    "name": "Nottingham City Hospital Department of Oncology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "York", 
                        "country": "United Kingdom"
                    }, 
                    "name": "York Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Czech Republic", 
                "France", 
                "Germany", 
                "Poland", 
                "Spain", 
                "Sweden", 
                "Switzerland", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Double-blind, Placebo-controlled, Phase I/II Trial of RNActive\u00ae-Derived Cancer Vaccine (CV9104) in Asymptomatic or Minimally Symptomatic Patients With Metastatic Castrate-refractory Prostate Cancer", 
        "overall_official": {
            "affiliation": "Universityhospital of T\u00fcbingen; Dept. of Urology", 
            "last_name": "Arnulf Stenzl, Prof. Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Czech Republic: State Institute for Drug Control", 
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "Germany: Paul-Ehrlich-Institut", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Sweden: Medical Products Agency", 
                "Switzerland: Swissmedic", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Safety Lead in Portion:\nPatients will receive CV9104 at a starting dose of 1920 \u00b5g in weeks 1, 2 and 3. Safety lead-in patients will be observed for DLTs until 1 week after Vaccination 3 (week 4). In case no DLTs will be observed vaccinations will continue in weeks 5, 7, 9, 12, 15, 18 and 24, then every 6 weeks for up to 12 months after the first vaccination and then every 3 months thereafter until one of the criteria for study treatment discontinuation is met", 
                "measure": "Phase I (Safety Lead-In): Occurence of dose-limiting toxicity (DLT) during the first 4 weeks of treatment (after administration of 3 vaccinations and after a 1 week observation period", 
                "safety_issue": "No", 
                "time_frame": "Up to 4 weeks"
            }, 
            {
                "measure": "Phase II (Randomised Portion): Overall Survival from time of randomisation- up to 3.5-4 years.", 
                "safety_issue": "No", 
                "time_frame": "Overall survival will be assessed during the lifetime of the study"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01817738"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression free survival from date of randomisation", 
                "safety_issue": "No", 
                "time_frame": "Every 3 months for up to 2 years"
            }, 
            {
                "measure": "Progression free survival from start of first subsequent systemic therapy", 
                "safety_issue": "No", 
                "time_frame": "Every 6 months until 2 years"
            }, 
            {
                "measure": "Percent change to maximal and to minimal PSA from baseline and before start of first subsequent systemic cancer therapy", 
                "safety_issue": "No", 
                "time_frame": "Every 3 months up to 2 years"
            }, 
            {
                "measure": "Cellular and humoral immune response rate against the 6 antigens encoded by CV9104", 
                "safety_issue": "No", 
                "time_frame": "Immune responses will be assessed at baseline ,in week 6 and week 24 after start of vaccination"
            }, 
            {
                "measure": "Absolute change from baseline FACT P score and subscores", 
                "safety_issue": "No", 
                "time_frame": "Assessments at baseline, weeks 5,9,18,24 and every 3 months for up to 2 years"
            }, 
            {
                "measure": "Absolute change from baseline EQ-5D score and pain sub-score", 
                "safety_issue": "No", 
                "time_frame": "Assessments at baseline, weeks 5, 9,18, 24 and thereafter every 3 months for up to 2 years"
            }
        ], 
        "source": "CureVac GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CureVac GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}